Modernatx, Inc.
Clinical trials sponsored by Modernatx, Inc., explained in plain language.
-
MRNA technology takes on the stomach flu: moderna launches norovirus vaccine trial
⭐️ VACCINE ⭐️ OngoingThis study tests two experimental mRNA vaccines, mRNA-1403 and mRNA-1405, designed to prevent norovirus, a common cause of severe vomiting and diarrhea. Around 1,400 healthy adults aged 18 to 80 will receive either a vaccine or a placebo. The main goals are to check safety and me…
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 23, 2026 23:50 UTC
-
New mRNA vaccine aims to shield toddlers from two winter viruses
⭐️ VACCINE ⭐️ OngoingThis early-stage trial tests two mRNA vaccines in children aged 5 to 24 months. One vaccine targets RSV alone, while the other targets both RSV and hMPV. The main goal is to check safety and how well the vaccines trigger an immune response. About 186 children will take part, and …
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 22, 2026 11:55 UTC
-
Massive trial launches for mRNA norovirus vaccine
⭐️ VACCINE ⭐️ OngoingThis study tests an experimental mRNA vaccine (mRNA-1403) to prevent norovirus, a highly contagious virus that causes severe vomiting and diarrhea. Over 37,000 adults aged 18 and older will receive either the vaccine or a placebo. The goal is to see if the vaccine safely reduces …
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 17, 2026 12:10 UTC
-
New COVID shots tested in 30,000 adults to stop symptomatic illness
⭐️ VACCINE ⭐️ OngoingThis study tests two updated mRNA COVID-19 vaccines (mRNA-1283 and mRNA-1273 variant formulation) in 30,000 healthy adults aged 50 to 64 who are not at high risk for severe COVID-19. The goal is to see if these vaccines prevent symptomatic COVID-19 compared to a placebo. Research…
Phase: PHASE4 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 17, 2026 12:06 UTC
-
Could this mRNA shot stop the virus behind mono and cancer?
⭐️ VACCINE ⭐️ OngoingThis early-stage study tests an experimental mRNA vaccine (mRNA-1195) designed to prevent Epstein-Barr virus (EBV) infection. About 482 healthy adults aged 18 to 55 will receive either the vaccine or a placebo. Researchers will monitor safety and measure the body's immune respons…
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 15, 2026 19:06 UTC
-
Could this mRNA vaccine stop the virus behind mono and certain cancers?
⭐️ VACCINE ⭐️ OngoingThis study is testing an experimental mRNA vaccine called mRNA-1189 to see if it can safely prevent Epstein-Barr virus (EBV) infection in healthy people aged 10 to 30. EBV is a common virus that can cause mononucleosis and has been linked to some cancers. The vaccine is given as …
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 15, 2026 19:02 UTC
-
New mRNA vaccine aims to shield transplant patients from dangerous virus
⭐️ VACCINE ⭐️ OngoingThis study tests an mRNA vaccine (mRNA-1647) to prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. About 84 participants will receive either the vaccine or a placebo. The goal is to see if the vaccine can safely prevent CMV after stopping stand…
Phase: PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 02, 2026 11:39 UTC
-
MRNA cancer vaccines enter human trials for multiple solid tumors
Disease control OngoingThis early-stage trial tests two experimental mRNA therapies, mRNA-4106 and mRNA-4200, in 42 people with advanced solid tumors like melanoma, lung, liver, and ovarian cancers. The study aims to check safety and find the right dose, either alone or combined with the immunotherapy …
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 23, 2026 12:00 UTC
-
New mRNA therapy aims to control blood sugar in rare genetic disease
Disease control OngoingThis early-stage trial tests an mRNA drug called mRNA-3745 in 15 adults and children with glycogen storage disease type 1a (GSD1a), a rare genetic condition that causes dangerously low blood sugar. The drug is given by IV infusion and aims to help the body produce a missing enzym…
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC
-
Personalized mRNA vaccine shows promise in fighting melanoma return
Disease control OngoingThis phase 2 trial is testing whether adding a personalized mRNA cancer vaccine (mRNA-4157) to the immunotherapy drug pembrolizumab can better prevent melanoma from coming back after surgery compared to pembrolizumab alone. The study involves 267 people with high-risk melanoma th…
Phase: PHASE2 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 22, 2026 12:01 UTC
-
New mRNA vaccine shows promise in fighting solid tumors
Disease control OngoingThis early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 11, 2026 12:12 UTC
-
Healthy volunteers needed to test new mRNA drug safety
Knowledge-focused OngoingThis early-stage study tests whether the experimental drug mRNA-0184 is safe in healthy adults. About 52 participants will receive one or more doses and be monitored for side effects. The study does not aim to treat any disease, but to gather important safety and drug-level infor…
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: Knowledge-focused
Last updated Jun 17, 2026 12:03 UTC
-
Thousands monitored for vaccine side effects in korean safety study
Knowledge-focused OngoingThis study tracks over 4,200 people in South Korea who received a SPIKEVAX COVID-19 vaccine to see if any side effects occur over time. Participants are aged 12 or older depending on the vaccine version. The goal is to gather real-world safety data, not to test if the vaccine wor…
Sponsor: ModernaTX, Inc. • Aim: Knowledge-focused
Last updated Jun 08, 2026 13:12 UTC